This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/managing-glaucoma-in-pregnancy-2026-evidence-and-consensus
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Managing Glaucoma in Pregnancy 2026: Evidence and Consensus
Evidence cutoff: July 24, 2026
Pregnancy does not automatically make glaucoma treatment unsafe, and stopping glaucoma medication without medical supervision can permanently threaten vision. The goal is to protect the pregnant patient’s optic nerve while reducing avoidable exposure of the fetus or breastfed infant to glaucoma medicines.
The best available evidence remains limited. There are no large randomized trials of glaucoma treatment during pregnancy. Current recommendations rely on medication labels, animal reproductive studies, pharmacokinetic research, retrospective case series, case reports, and expert consensus. The most current major guidance includes the 2026 American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern, the American Glaucoma Society and Canadian Glaucoma Society practical guide, and updated clinical reviews. ()
> Important: This article is educational and cannot replace individualized care from a glaucoma specialist, obstetric clinician, and—when appropriate—a pediatric or neonatal clinician.
Key recommendations at a glance
Plan before conception whenever possible. Establish a target pressure, document the optic nerve and visual field, review medications, and consider laser treatment or surgery before pregnancy if glaucoma is advanced or difficult to control.
Do not assume that pregnancy will lower pressure enough. Intraocular pressure often falls, but some patients with established glaucoma experience pressure elevation or visual field progression.
Use the fewest medicines at the lowest effective exposure. Punctal occlusion and gentle eyelid closure should be used after every drop.
Brimonidine is commonly preferred when a glaucoma drop is needed during pregnancy, but it should be stopped before delivery and avoided during breastfeeding because of possible infant central nervous system depression and apnea.
Timolol may be used selectively, particularly when the maternal benefit is important, but fetal growth and heart rate should be considered, and newborns may require observation after late-pregnancy exposure.
Topical carbonic anhydrase inhibitors such as dorzolamide or brinzolamide are possible alternatives when needed, although human pregnancy and milk data are limited.
Oral acetazolamide is generally reserved for serious or refractory pressure elevation. It is often considered acceptable during breastfeeding, but exposure near delivery has occasionally been associated with temporary neonatal metabolic acidosis.
Prostaglandin analogues are not first-line during pregnancy because of a theoretical risk of uterine contraction or premature labor and limited human data.
Selective laser trabeculoplasty may reduce or eliminate medication exposure. Guidance differs slightly on first-trimester elective treatment, so timing should depend on disease severity and urgency.
Incisional surgery is unusual but justified when vision is at meaningful risk. If it cannot be deferred, the second trimester is generally preferred, with local anesthesia and avoidance of antimetabolites whenever possible.
How pregnancy changes intraocular pressure
Normal physiologic changes
Intraocular pressure usually decreases during pregnancy. Proposed explanations include:
Increased aqueous humor outflow related to hormonal changes
Reduced episcleral venous pressure
Effects of progesterone and relaxin
Pregnancy-related changes in blood chemistry and vascular physiology
One study found that average intraocular pressure in the first trimester was approximately 2 millimeters of mercury higher than in the third trimester. Another study reported an approximately 19.6% reduction in women without ocular hypertension and a 24.4% reduction in women with ocular hypertension, although these studies were relatively small and older. ()
Pregnancy can also change corneal thickness and biomechanics, which may influence applanation pressure readings. For this reason, clinicians should interpret pressure trends together with the optic nerve, retinal nerve fiber layer imaging, and visual field—not pressure alone. In one review, both intraocular pressure and central corneal thickness had returned toward first-trimester values by approximately three months after delivery. ()
Why glaucoma can still worsen
The average fall in pressure does not protect every patient. In a retrospective series of 28 eyes from 15 women with glaucoma:
57.1% had stable pressure without visual field progression.
17.9% developed visual field progression even though pressure was stable or increased.
17.9% developed pressure elevation without documented visual field progression.
Two eyes had inconclusive data.
Many patients required glaucoma medication during pregnancy. ()
The practical lesson is important: a lower pregnancy pressure does not prove that glaucoma is stable, and a normal-looking pressure does not exclude progression.
Monitoring during pregnancy and after delivery
Minimum monitoring
At a minimum, a pregnant patient with established glaucoma should generally be assessed at least once during each trimester. This is a consensus-based recommendation rather than one supported by a large pregnancy trial. ()
A useful examination may include:
Visual acuity
Intraocular pressure using the same method when possible
Optic nerve examination and photographs
Visual field testing when the patient can perform it reliably
Optical coherence tomography of the retinal nerve fiber layer and ganglion cell layer
Gonioscopy when angle status is uncertain or angle closure is possible
Medication review, adherence, and drop technique
Heart rate and respiratory history if a beta-blocker is being used
Practical monitoring intervals
The following schedule is a practical risk-based framework, not a universally validated guideline:
For the full table, please open this article on visualfieldtest.com.
A visual field and structural baseline should ideally be obtained before conception. Repeating both tests once per trimester may be reasonable for moderate or advanced disease if the patient can tolerate testing, but excessive testing can create fatigue and unreliable results.
Postpartum pressure rebound
Pressure may rise again after delivery as pregnancy-related physiologic changes resolve. This may be especially important when medication was reduced or stopped during pregnancy. A postpartum plan should therefore be made before delivery rather than waiting for symptoms, because glaucoma progression is often silent. ()
Medication safety during pregnancy and breastfeeding
A note about “pregnancy categories”
Many older articles describe glaucoma medicines as Category B or Category C. The United States Food and Drug Administration replaced the former letter categories with descriptive pregnancy and lactation labeling in 2015. The older categories may still appear in reviews, but they should not be interpreted as modern, precise safety rankings. The current labeling emphasizes the quality of human data, animal findings, and the balance between maternal benefit and fetal or infant risk. ()
Medication comparison
For the full table, please open this article on visualfieldtest.com.
Brimonidine
Brimonidine is frequently described as the preferred first medication during pregnancy because animal studies did not demonstrate fetal malformations at exposures substantially above typical ophthalmic exposure. However, current United States product labeling states that human pregnancy data are inadequate and that the medicine should be used only when the maternal benefit justifies potential fetal risk. ()
The more important issue is the newborn. Brimonidine crosses the blood-brain barrier and has been associated with central nervous system depression, excessive sleepiness, hypotension, bradycardia, and apnea in infants exposed directly to the medication. Animal studies also demonstrate transfer into milk. For this reason, the American Glaucoma Society handout and product labeling recommend stopping brimonidine before delivery and avoiding it during breastfeeding. ()
The precise stopping date is not established by high-quality evidence. A practical plan is to discontinue it well before expected delivery, with the exact timing based on disease severity, the alternative treatment, and obstetric and neonatal advice.
There are a few reports of breastfeeding without apparent harm, but these involve very small numbers and sometimes multiple medications. LactMed therefore acknowledges the limited reassuring reports while also noting that manufacturers and many clinicians recommend avoiding brimonidine because the potential consequences in a newborn could be serious. ()
Timolol and other beta-blockers
Topical timolol is systemically absorbed and can cross the placenta. Potential fetal or neonatal concerns include a slow heart rate and low blood pressure. Current clinical guidance supports selective use with the lowest effective exposure and consideration of fetal heart-rate and growth monitoring, especially with prolonged or late-pregnancy treatment. ()
The American Glaucoma Society has suggested that clinicians may consider reducing exposure—for example, using a lower concentration when clinically adequate—but patients should not change concentr
Support the show
